I guess we've learned a few things, and if I had any recommendations, one would be good monitoring. We've learned to make sure there are no counter effects. The other thing is to make it evidence-based, ensure that whatever is coming out is evidence-based. I think the OAG talked about that and I take that as very important, as well as understanding where the cost and the cost drivers are, and maybe at the end, the cost savings.
The other thing is that we're using a term more and more in the department to “go low and go slow”, to ensure that when you're starting with your prescriptions and the approvals and that, you start slowly and at lower levels. I think marijuana caught us maybe a little by surprise. When the regulations changed, we were perhaps a little slow to react to that. We went from no more than a couple of grams a day and 100 veterans using it, to 3,000 using it within a year or 18 months.
That's where I would go. Make sure you have the data, the evidence, and then know where the cost drivers are.